Compare
Up to four compounds, side by side.
Useful for choosing between similar peptides or planning a stack.
Add a peptide
| Attribute | GLP-1 Agonist Semaglutide | Mitochondrial MOTS-c |
|---|---|---|
| Summary | The category-defining GLP-1 for weight loss and metabolic health. | Mitochondrial peptide for metabolic flexibility and exercise capacity. |
| Mechanism | Long-acting GLP-1 receptor agonist. Slows gastric emptying, suppresses appetite, and improves glycemic control. | Mitochondrial-derived peptide. Activates AMPK, improves insulin sensitivity and mitochondrial function. |
| Top outcomes |
|
|
| Evidence | established | emerging |
| Half-life | ~7 days | Several hours |
| Administration | subq, oral | subq |
| Legal status | rx only | research only |
| Safety | GI side effects (nausea, constipation) common. Lean-mass loss possible without resistance training. | Limited human safety data; well tolerated anecdotally. |